{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:57:48Z","timestamp":1789689468897,"version":"4.0.1"},"reference-count":54,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,26]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Targeted therapies can induce responses in patients with relapsed\/refractory T-cell lymphoma (R\/R TCL) but are not curative. Genetic mutations associated with epigenetic and transcriptional dysregulation are common in many TCL subtypes, and drugs that modulate the epigenome and that target transcriptional regulators have synergistic activity in TCL. We hypothesized that fixed duration treatment with multiagent combinations of these drugs could produce deep responses leading to durable remissions. In a phase 1 trial, we tested escalating doses of lenalidomide added to romidepsin, azacitidine, and dexamethasone (RAdR) for patients with R\/R TCL. The primary objective was to identify the maximum tolerated dose (MTD) of lenalidomide that could safely be used in RAdR. Secondary end points included response rate, survival, and markers of immune activation. Twenty-six patients enrolled and 21 were evaluable for response. Adverse events were predominantly gastrointestinal and hematologic. Grade 3\/4 thrombocytopenia and neutropenia occurred in 19% and 21% of cycles, respectively. The MTD of lenalidomide was 20 mg. Among 9 patients treated at the MTD the objective response rate was 89% and complete response rate 22%. At 1 year, the estimated rate of progression-free survival was 14% and overall survival was 66%. Cell line models of anaplastic large cell lymphoma were interrogated to explore the activity of drug combinations in responding genetic subtypes. RAdR demonstrated activity in patients with highly refractory TCL but did not induce durable responses. This novel combination effectively bridged some patients with refractory TCL to consolidation such as allogeneic transplantation. This trial was registered at www.ClinicalTrials.gov as NCT04447027.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019186","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T17:08:47Z","timestamp":1772644127000},"page":"3398-3408","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["A phase 1 trial of romidepsin, azacitidine, dexamethasone, and lenalidomide in relapsed or refractory T-cell lymphoma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3940-4451","authenticated-orcid":false,"given":"Max J.","family":"Gordon","sequence":"first","affiliation":[{"name":"1Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milos D.","family":"Miljkovic","sequence":"additional","affiliation":[{"name":"1Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD"},{"name":"2Cartesian Therapeutics, Gaithersburg, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0898-9478","authenticated-orcid":false,"given":"Paige","family":"Milhon","sequence":"additional","affiliation":[{"name":"1Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3123-6844","authenticated-orcid":false,"given":"Rahul","family":"Lakhotia","sequence":"additional","affiliation":[{"name":"1Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9661-4570","authenticated-orcid":false,"given":"Christopher","family":"Melani","sequence":"additional","affiliation":[{"name":"1Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Johnson","sequence":"additional","affiliation":[{"name":"1Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonita","family":"Bryant","sequence":"additional","affiliation":[{"name":"1Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7688-1439","authenticated-orcid":false,"given":"Stefania","family":"Pittaluga","sequence":"additional","affiliation":[{"name":"3Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4632-0301","authenticated-orcid":false,"given":"Elaine S.","family":"Jaffe","sequence":"additional","affiliation":[{"name":"3Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Conlon","sequence":"additional","affiliation":[{"name":"1Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis M.","family":"Staudt","sequence":"additional","affiliation":[{"name":"1Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wyndham H.","family":"Wilson","sequence":"additional","affiliation":[{"name":"1Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0278-2635","authenticated-orcid":false,"given":"Mark","family":"Roschewski","sequence":"additional","affiliation":[{"name":"1Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Ng","sequence":"additional","affiliation":[{"name":"1Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"issue":"11","key":"2026052610381935000_bib1","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2026052610381935000_bib2","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"2026052610381935000_bib3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc1111708","article-title":"TET2 and DNMT3A mutations in human T-cell lymphoma","volume":"366","author":"Couronn\u00e9","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"2026052610381935000_bib4","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","article-title":"A targeted mutational landscape of angioimmunoblastic T-cell lymphoma","volume":"123","author":"Odejide","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2026052610381935000_bib5","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","article-title":"Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters","volume":"120","author":"Lemonnier","year":"2012","journal-title":"Blood"},{"issue":"20","key":"2026052610381935000_bib6","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1182\/blood-2014-05-578575","article-title":"The oncogenic transcription factor IRF4 is regulated by a novel CD30\/NF-kB positive feedback loop in peripheral T-cell lymphoma","volume":"125","author":"Boddicker","year":"2015","journal-title":"Blood"},{"issue":"19","key":"2026052610381935000_bib7","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.3390\/cancers16193368","article-title":"The tumor microenvironment as a therapeutic target in cutaneous T cell lymphoma","volume":"16","author":"Kwantwi","year":"2024","journal-title":"Cancers"},{"issue":"19","key":"2026052610381935000_bib8","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2026052610381935000_bib9","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/s41375-025-02563-0","article-title":"Discrete genetic subtypes and tumor microenvironment signatures correlate with peripheral T-cell lymphoma outcomes","volume":"39","author":"Suehara","year":"2025","journal-title":"Leukemia"},{"issue":"2","key":"2026052610381935000_bib10","doi-asserted-by":"crossref","first-page":"100646","DOI":"10.1016\/j.modpat.2024.100646","article-title":"Refining diagnostic subtypes of peripheral T-cell lymphoma using a multiparameter approach","volume":"38","author":"Amador","year":"2025","journal-title":"Mod Pathol"},{"issue":"8","key":"2026052610381935000_bib11","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1158\/1078-0432.CCR-15-1435","article-title":"Romidepsin and azacitidine synergize in their epigenetic modulatory effects to induce apoptosis in CTCL","volume":"22","author":"Rozati","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2026052610381935000_bib12","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1038\/s41375-022-01571-8","article-title":"Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma","volume":"36","author":"Wong","year":"2022","journal-title":"Leukemia"},{"issue":"10","key":"2026052610381935000_bib13","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1038\/bcj.2015.83","article-title":"Romidepsin targets multiple survival signaling pathways in malignant T cells","volume":"5","author":"Valdez","year":"2015","journal-title":"Blood Cancer J"},{"issue":"3","key":"2026052610381935000_bib14","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2141.2011.08689.x","article-title":"Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response","volume":"154","author":"Lopez-Girona","year":"2011","journal-title":"Br J Haematol"},{"issue":"1","key":"2026052610381935000_bib15","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1038\/s41467-018-04356-9","article-title":"Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models","volume":"9","author":"Ng","year":"2018","journal-title":"Nat Commun"},{"issue":"13","key":"2026052610381935000_bib16","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood.2021014701","article-title":"Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1","volume":"139","author":"Wu","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2026052610381935000_bib17","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood-2015-01-625004","article-title":"Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds","volume":"126","author":"Lagrue","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2026052610381935000_bib18","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2012-02-411678","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Ramsay","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2026052610381935000_bib19","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1158\/1078-0432.CCR-15-1435","article-title":"Romidepsin and azacitidine synergize in their epigenetic modulatory effects to induce apoptosis in CTCL","volume":"22","author":"Rozati","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2026052610381935000_bib20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bjh.13566","article-title":"The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma","volume":"171","author":"Marchi","year":"2015","journal-title":"Br J Haematol"},{"issue":"10","key":"2026052610381935000_bib21","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1080\/15384047.2016.1219820","article-title":"The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines","volume":"17","author":"Cosenza","year":"2016","journal-title":"Cancer Biol Ther"},{"issue":"25","key":"2026052610381935000_bib22","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"2026052610381935000_bib23","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"issue":"18","key":"2026052610381935000_bib24","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2026052610381935000_bib25","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16","key":"2026052610381935000_bib26","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J Clin Oncol"},{"issue":"14","key":"2026052610381935000_bib27","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1080\/10428194.2023.2256908","article-title":"Influence of treatment intensity and medical comorbidities in older adults with peripheral T cell lymphoma","volume":"64","author":"Gordon","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2026052610381935000_bib28","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1182\/bloodadvances.2024014674","article-title":"Global outcomes and prognosis for relapsed\/refractory mature T-cell and NK-cell lymphomas: results from PETAL Consortium","volume":"9","author":"Han","year":"2024","journal-title":"Blood Adv"},{"issue":"6","key":"2026052610381935000_bib29","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/ajh.25463","article-title":"Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry","volume":"94","author":"Stuver","year":"2019","journal-title":"Am J Hematol"},{"issue":"5","key":"2026052610381935000_bib30","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/bjh.14477","article-title":"The survival outcome of patients with relapsed\/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma","volume":"176","author":"Chihara","year":"2017","journal-title":"Br J Haematol"},{"issue":"6","key":"2026052610381935000_bib31","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026052610381935000_bib32","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/S2352-3026(24)00102-9","article-title":"Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study","volume":"11","author":"Dupuis","year":"2024","journal-title":"Lancet Haematol"},{"issue":"22","key":"2026052610381935000_bib33","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"issue":"29","key":"2026052610381935000_bib34","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J Clin Oncol"},{"issue":"13","key":"2026052610381935000_bib35","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","article-title":"A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial","volume":"49","author":"Morschhauser","year":"2013","journal-title":"Eur J Cancer"},{"issue":"34","key":"2026052610381935000_bib36","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1200\/JCO.2016.67.7732","article-title":"Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia\/lymphoma: ATLL-002","volume":"34","author":"Ishida","year":"2016","journal-title":"J Clin Oncol"},{"issue":"16","key":"2026052610381935000_bib37","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"issue":"19","key":"2026052610381935000_bib38","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1182\/bloodadvances.2023009767","article-title":"Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma","volume":"7","author":"Ruan","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"2026052610381935000_bib39","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/annonc\/mdx097","article-title":"International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)","volume":"28","author":"Younes","year":"2017","journal-title":"Ann Oncol"},{"issue":"18","key":"2026052610381935000_bib40","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026052610381935000_bib41","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.2008.18.2428","article-title":"Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting","volume":"27","author":"Tsukasaki","year":"2009","journal-title":"J Clin Oncol"},{"issue":"24","key":"2026052610381935000_bib42","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood.2019000779","article-title":"Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry","volume":"134","author":"Amador","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2026052610381935000_bib43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses","volume":"7","author":"Coiffier","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"23","key":"2026052610381935000_bib44","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J Clin Oncol"},{"issue":"13","key":"2026052610381935000_bib45","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1182\/blood-2018-03-838524","article-title":"Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements","volume":"132","author":"Luchtel","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2026052610381935000_bib46","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes","volume":"124","author":"Parrilla Castellar","year":"2014","journal-title":"Blood"},{"issue":"15","key":"2026052610381935000_bib47","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1182\/blood-2013-04-497933","article-title":"PRDM1\/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma","volume":"122","author":"Boi","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2026052610381935000_bib48","doi-asserted-by":"crossref","first-page":"101472","DOI":"10.1016\/j.xcrm.2024.101472","article-title":"STAT3 couples activated tyrosine kinase signaling to the oncogenic core transcriptional regulatory circuitry of anaplastic large cell lymphoma","volume":"5","author":"Prutsch","year":"2024","journal-title":"Cell Rep Med"},{"issue":"1","key":"2026052610381935000_bib49","doi-asserted-by":"crossref","first-page":"13119","DOI":"10.1038\/s41598-025-95741-0","article-title":"Decitabine promotes the differentiation of poorly differentiated gastric cancer cells and enhances the sensitivity of NK cell cytotoxicity via TNF-\u03b1","volume":"15","author":"Lv","year":"2025","journal-title":"Sci Rep"},{"issue":"3","key":"2026052610381935000_bib50","doi-asserted-by":"crossref","first-page":"e1500","DOI":"10.1002\/cti2.1500","article-title":"Synergistic integration of histone deacetylase inhibitors apparently enhances the cytokine-induced killer cell efficiency in multiple myeloma via the NKG2D pathway","volume":"13","author":"Pu","year":"2024","journal-title":"Clin Transl Immunol"},{"issue":"1","key":"2026052610381935000_bib51","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1158\/1078-0432.CCR-24-1913","article-title":"A phase II study of acimtamig (AFM13) in patients with CD30-positive, relapsed or refractory peripheral T-cell lymphomas","volume":"31","author":"Kim","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2026052610381935000_bib52","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1080\/10428194.2024.2326847","article-title":"A phase 1 study of interleukin-15 in combination with avelumab in relapsed or refractory T-cell lymphoma","volume":"65","author":"Gordon","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2026052610381935000_bib53","doi-asserted-by":"crossref","first-page":"100054","DOI":"10.1016\/j.bneo.2024.100054","article-title":"A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies","volume":"2","author":"Gordon","year":"2025","journal-title":"Blood Neoplasia"},{"issue":"3","key":"2026052610381935000_bib54","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/bloodadvances.2021006440","article-title":"Interleukin-15 augments NK cell-mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies","volume":"7","author":"Miljkovic","year":"2023","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/10\/3398\/2518712\/blooda_adv-2025-019186-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/10\/3398\/2518712\/blooda_adv-2025-019186-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:38:27Z","timestamp":1779806307000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/10\/3398\/566588\/A-phase-1-trial-of-romidepsin-azacitidine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,5,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019186","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,26]]},"published":{"date-parts":[[2026,5,13]]}}}